article thumbnail

Can your LNP manufacturing platform cope with the pace of the mRNA revolution?

Pharmaceutical Technology

GlobalData pharmaceutical analysts project that RNA-based gene therapies for oncology will grow from zero in 2022 to $4.6 Makowiecki says the same benefits apply to the development and manufacture of RNA-LNPs as in other biopharmaceutical manufacturing, while accommodating for their unique characteristics. billion by 2028.

article thumbnail

Can liquid biopsies transform precision medicine?

Drug Discovery World

6 Genomic (DNA) analysis provides information on past mutations acquired during the evolutionary history of the tumour, whereas transcriptomic (RNA) analysis provides accurate phenotypic information of the tumour at the time of sampling 10 , thus CTCs provide prospective information on the evolving tumour or metastasis. 22 Ring et al.,

article thumbnail

Predictive diagnostics: closing the precision medicine gap

Drug Discovery World

Before drugs make it to market they have to pass through a gauntlet of stages involved in clinical trials. As such, patient selection for clinical trials has become an increasingly critical consideration for drug trial success. About the author . Jarret Glasscock is a geneticist and computational biologist.